Additive Clinical Utility of Microsatellite Instability and Tumor Mutational Burden to Predict Immune Checkpoint Inhibitor Effectiveness in Metastatic Castration-Resistant Prostate Cancer
Authors:
- Nicolas SayeghNSNicolas Sayegh
- Ryon P. GrafRGRyon P. Graf
- Umang SwamiUmang Swami
- Zeynep Irem OzayZOZeynep Irem Ozay
- Chadi Hage ChehadeCCChadi Hage Chehade
- Julia A. ElvinJEJulia A. Elvin
- Douglas LinDLDouglas Lin
- Julia C.F. QuintanilhaJQJulia C.F. Quintanilha
- Gerald LiGLGerald Li
- Alan H. BryceABAlan H. Bryce
- Rana R. McKayRMRana R. McKay
- Jeffrey S. RossJRJeffrey S. Ross
Open Access
- 4 December 2025
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (4) , 801-812
Abstract
Purpose: Immune checkpoint inhibitors (ICI) have shown limited efficacy in unselected patients with metastatic castration-resistant prostate cancer (mCRPC). However, ICIs are approved for biomarker-defined subsets: microsatellite instability–high (MSI-H) and/or high tumor mutational burden (TMB-H). The efficacy of ICIs in TMB-H but not MSI-H disease remains unclear, and limited data exist evaluating ICI outcomes associated with blood-based MSI (bMSI) in mCRPC. Experimental Design: This study used the United States–based deidentified Flatiron Health–Foundation Medicine prostate cancer Clinico-Genomic Database. Patients with tissue-assessed MSI (tMSI) and TMB (tTMB) status by an algorithm supporting an FDA-approved CDx for pembrolizumab were included if treated with single-agent ICI. Separately, outcomes on ICI associated with bMSI were assessed, including if treated with single-agent ICI or taxane. Results: Among 2,965 patients with mCRPC, tMSI-H (3.2%) was nearly always also tTMB ≥10 mut/Mb (4.7%). In 84 ICI-treated patients, time to next treatment (TTNT) and overall survival (OS) were more favorable in tMSI-H with any TMB [TTNT HR, 0.18; 95% confidence interval (CI), 0.09–0.37 and OS HR, 0.32; 95% CI, 0.15–0.66] and tTMB ≥10 without tMSI-H (TTNT HR, 0.18; 95% CI, 0.04–0.48 and OS HR, 0.20; 95% CI, 0.05–0.77) compared with tTMB <10 without tMSI-H group. In intrapatient assessments, patients with tTMB ≥10 had more favorable TTNT with subsequent ICI versus prior taxane. Detection of bMSI-H was associated with more favorable TTNT on ICI (HR, 0.34; 95% CI, 0.14–0.83) and OS (HR, 0.21; 95% CI, 0.06–0.75) when tumor fraction ≥1%. Conclusions: These findings add support for tTMB and tMSI in predicting ICI monotherapy benefit in mCRPC and provide evidence supporting bMSI testing when tissue is unavailable.Keywords
All Related Versions
This publication has 33 references indexed in Scilit:
- LBA67 Cabozantinib (C) plus atezolizumab (A) versus 2nd novel hormonal therapy (NHT) in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC): Final overall survival (OS) results of the phase III, randomized, CONTACT-02 studyAnnals of Oncology, 2024
- Ipilimumab with nivolumab in molecularly selected patients with castration-resistant prostate cancer: primary analysis of the phase II INSPIRE trialAnnals of Oncology, 2024
- Tumor Mutational Burden in Metastatic Castration-Resistant Prostate Cancer and Response to Checkpoint InhibitionJAMA Oncology, 2024
- Clinical and Genomic Factors Associated with Greater Tumor Mutational Burden in Prostate CancerEuropean Urology Open Science, 2023
- Off-label use of immune checkpoint inhibitors for the treatment of solid tumors: analysis of a nationwide patient sampleJournal of Cancer Research and Clinical Oncology, 2023
- Not all TMB assays are the same: Clinical validity of robust algorithmic germline filteringCancer Cell, 2023
- Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy in Patients With Metastatic Colorectal Cancer With Measures of Microsatellite Instability, Mismatch Repair, or Tumor Mutational BurdenJAMA Network Open, 2023
- Analysis of a Real-World Progression Variable and Related Endpoints for Patients with Five Different Cancer TypesAdvances in Therapy, 2022
- Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy by Tumor Mutational Burden in Metastatic Castration-Resistant Prostate CancerJAMA Network Open, 2022
- Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studiesStatistics in Medicine, 2015